Protalix BioTherapeutics, Inc. (PLX) income statement
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3043% below fair value
$3.06+0.04 (+1.32%)
Close on Nov 19, 2026Market cap $246.55MP/E 13.3Yield –
Protalix BioTherapeutics, Inc. financial ratios
See a number that looks wrong?